Pemafibrate
Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.
In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1mg tablets.[1]
References
|
---|
AhR | Agonists |
- Arachidonic acid metabolites (e.g., lipoxin A4, prostaglandin G2)
- Dietary carotenoids
- Flutamide
- Halogenated aromatic hydrocarbons (e.g., polychlorinated dibenzodioxins (e.g., TCDD), dibenzofurans, biphenyls)
- Modified low-density lipoproteins
- Polycyclic aromatic hydrocarbons (e.g., 3-methylcholanthrene, benzo[a]pyrene, benzanthracenes, benzoflavones (e.g., beta-naphthoflavone))
- Tetrapyroles (e.g., bilirubin)
- Tryptophan derivatives (e.g., indigo dye, indirubin)
|
---|
Antagonists | |
---|
|
---|
CAR | |
---|
ERR | ERRα | |
---|
ERRβ | Agonists |
- DY-131 (GSK-9089)
- GSK-4716 (GW-4716)
|
---|
Antagonists | |
---|
|
---|
ERRγ | |
---|
|
---|
FXR | |
---|
LXR | |
---|
PPAR | |
---|
PXR | |
---|
RAR | Agonists | |
---|
Antagonists |
- BMS-195614
- BMS-493
- CD-2665
- ER-50891
- LE-135
- MM-11253
|
---|
Others |
- Retinoic acid metabolism inhibitors: Liarozole
|
---|
|
---|
RXR | Agonists | |
---|
Antagonists |
- HX-531
- HX-630
- LG-100754
- PA-452
- UVI-3003
- HX-603
- LE135 (RAR beta selective)
- LE-540
- CD3254
- PA-451
- PA-452
- Rhein
- HX-711
- 6-(N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(E)-styrylphenyl)amino)nicotinic acid
|
---|
|
---|
SHR | AR | See here instead. |
---|
ER | See here instead. |
---|
PR | See here instead. |
---|
GR | See here instead. |
---|
MR | See here instead. |
---|
VDR | |
---|
|
---|
THR | |
---|
- See also
- Receptor/signaling modulators
|